Regression of left ventricular hypertrophy with isradipine in previously untreated hypertensive patients.
The regression of left ventricular hypertrophy (LVH) is considered a desirable goal of antihypertensive treatment. Isradipine was used as first-line antihypertensive treatment in 15 patients who had mild-to-moderate hypertension and LVH, and who were studied before and after 6 months of treatment. Left ventricular mass and function were assessed by Doppler echocardiography. Systolic and diastolic blood pressure were reduced from 161 +/- 14 mm Hg and 103 +/- 3 mm Hg to 136 +/- 8 mm Hg and 87 +/- 6 mm Hg, respectively (P < .001). The interventricular septal thickness was reduced by 11.9% (P < .001), posterior wall thickness by 11.1% (P < .001), left ventricular end-diastolic diameter by 2%, and left ventricular mass index by 17% (P < .02). In conclusion, 6 months of antihypertensive treatment of mild-to-moderate hypertension with isradipine achieves a significant regression (17%) of LVH.
Manolis
A J
AJ
Cardiology Department, Tzanio Hospital, Piraeus, Greece.
Kolovou
G
G
Handanis
S
S
Athanasopoulos
G
G
Antonopoulos
S
S
Cokkinos
D V
DV
D000328:Adult; D015150:Echocardiography, Doppler; D005260:Female; D006352:Heart Ventricles / Q000000981:diagnostic imaging; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy*; D017379:Hypertrophy, Left Ventricular / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000209:etiology; D017275:Isradipine / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome
D017275:Isradipine